Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TNF inhibitor

DRUG CLASS:

TNF inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

thalidomide (15)

thalidomide (15)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	thalidomide Sensitive: A1 - Approval thalidomide Sensitive : A1	thalidomide Sensitive: A1 - Approval thalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	thalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval thalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	thalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval thalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	thalidomide Sensitive: A2 - Guideline thalidomide Sensitive : A2	thalidomide Sensitive: A2 - Guideline thalidomide Sensitive : A2
CRBN overexpression	Multiple Myeloma	CRBN overexpression	Multiple Myeloma	thalidomide Resistant: C3 – Early Trials thalidomide Resistant : C3	thalidomide Resistant: C3 – Early Trials thalidomide Resistant : C3
DDB1 overexpression	Multiple Myeloma	DDB1 overexpression	Multiple Myeloma	thalidomide Sensitive: C3 – Early Trials thalidomide Sensitive : C3	thalidomide Sensitive: C3 – Early Trials thalidomide Sensitive : C3
CUL4A overexpression	Multiple Myeloma	CUL4A overexpression	Multiple Myeloma	thalidomide Sensitive: C3 – Early Trials thalidomide Sensitive : C3	thalidomide Sensitive: C3 – Early Trials thalidomide Sensitive : C3
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	thalidomide Resistant: C3 – Early Trials thalidomide Resistant : C3	thalidomide Resistant: C3 – Early Trials thalidomide Resistant : C3
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	thalidomide Resistant: C3 – Early Trials thalidomide Resistant : C3	thalidomide Resistant: C3 – Early Trials thalidomide Resistant : C3
CRBN expression	Multiple Myeloma	CRBN expression	Multiple Myeloma	thalidomide Sensitive: C3 – Early Trials thalidomide Sensitive : C3	thalidomide Sensitive: C3 – Early Trials thalidomide Sensitive : C3
CUL4A expression	Multiple Myeloma	CUL4A expression	Multiple Myeloma	thalidomide Sensitive: C3 – Early Trials thalidomide Sensitive : C3	thalidomide Sensitive: C3 – Early Trials thalidomide Sensitive : C3
CRBN R283K	Multiple Myeloma	CRBN R283K	Multiple Myeloma	thalidomide Resistant: C4 – Case Studies thalidomide Resistant : C4	thalidomide Resistant: C4 – Case Studies thalidomide Resistant : C4
CRBN Q99	Multiple Myeloma	CRBN Q99	Multiple Myeloma	thalidomide Resistant: C4 – Case Studies thalidomide Resistant : C4	thalidomide Resistant: C4 – Case Studies thalidomide Resistant : C4
Chr t(11;14)(q13;q32)	Multiple Myeloma	Chr t(11;14)(q13;q32)	Multiple Myeloma	thalidomide Resistant: C4 – Case Studies thalidomide Resistant : C4	thalidomide Resistant: C4 – Case Studies thalidomide Resistant : C4
MUC4 expression	HER2 Positive Breast Cancer	MUC4 expression	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki + INB03 Sensitive: D – Preclinical fam-trastuzumab deruxtecan-nxki + INB03 Sensitive : D	fam-trastuzumab deruxtecan-nxki + INB03 Sensitive: D – Preclinical fam-trastuzumab deruxtecan-nxki + INB03 Sensitive : D